KR20230035435A - 암의 치료에서 항-cd47 제제의 치료적으로 효과적인 용량을 결정하고 달성하는 방법 - Google Patents

암의 치료에서 항-cd47 제제의 치료적으로 효과적인 용량을 결정하고 달성하는 방법 Download PDF

Info

Publication number
KR20230035435A
KR20230035435A KR1020237006777A KR20237006777A KR20230035435A KR 20230035435 A KR20230035435 A KR 20230035435A KR 1020237006777 A KR1020237006777 A KR 1020237006777A KR 20237006777 A KR20237006777 A KR 20237006777A KR 20230035435 A KR20230035435 A KR 20230035435A
Authority
KR
South Korea
Prior art keywords
dose
agent
priming
administered
hu5f9
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020237006777A
Other languages
English (en)
Korean (ko)
Inventor
어빙 엘. 와이즈먼
마크 피. 차오
라빈드라 마제티
지에 리우
옌스-피터 볼크메어
Original Assignee
더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티
더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티, 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 filed Critical 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티
Priority to KR1020247002294A priority Critical patent/KR20240016445A/ko
Publication of KR20230035435A publication Critical patent/KR20230035435A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
KR1020237006777A 2016-04-15 2017-04-14 암의 치료에서 항-cd47 제제의 치료적으로 효과적인 용량을 결정하고 달성하는 방법 Ceased KR20230035435A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020247002294A KR20240016445A (ko) 2016-04-15 2017-04-14 암의 치료에서 항-cd47 제제의 치료적으로 효과적인 용량을 결정하고 달성하는 방법

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201662323330P 2016-04-15 2016-04-15
US62/323,330 2016-04-15
US201662427679P 2016-11-29 2016-11-29
US62/427,679 2016-11-29
KR1020187032126A KR102505253B1 (ko) 2016-04-15 2017-04-14 암의 치료에서 항-cd47 제제의 치료적으로 효과적인 용량을 결정하고 달성하는 방법
PCT/US2017/027662 WO2017181033A1 (en) 2016-04-15 2017-04-14 Methods for determining and achieving therapeutically effective doses of anti-cd47 agents in treatment of cancer

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020187032126A Division KR102505253B1 (ko) 2016-04-15 2017-04-14 암의 치료에서 항-cd47 제제의 치료적으로 효과적인 용량을 결정하고 달성하는 방법

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020247002294A Division KR20240016445A (ko) 2016-04-15 2017-04-14 암의 치료에서 항-cd47 제제의 치료적으로 효과적인 용량을 결정하고 달성하는 방법

Publications (1)

Publication Number Publication Date
KR20230035435A true KR20230035435A (ko) 2023-03-13

Family

ID=60042716

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020237006777A Ceased KR20230035435A (ko) 2016-04-15 2017-04-14 암의 치료에서 항-cd47 제제의 치료적으로 효과적인 용량을 결정하고 달성하는 방법
KR1020247002294A Pending KR20240016445A (ko) 2016-04-15 2017-04-14 암의 치료에서 항-cd47 제제의 치료적으로 효과적인 용량을 결정하고 달성하는 방법
KR1020187032126A Active KR102505253B1 (ko) 2016-04-15 2017-04-14 암의 치료에서 항-cd47 제제의 치료적으로 효과적인 용량을 결정하고 달성하는 방법

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020247002294A Pending KR20240016445A (ko) 2016-04-15 2017-04-14 암의 치료에서 항-cd47 제제의 치료적으로 효과적인 용량을 결정하고 달성하는 방법
KR1020187032126A Active KR102505253B1 (ko) 2016-04-15 2017-04-14 암의 치료에서 항-cd47 제제의 치료적으로 효과적인 용량을 결정하고 달성하는 방법

Country Status (12)

Country Link
US (3) US11472878B2 (enExample)
EP (3) EP4349412A3 (enExample)
JP (3) JP7532009B2 (enExample)
KR (3) KR20230035435A (enExample)
CN (3) CN115350276A (enExample)
AU (2) AU2017250809B2 (enExample)
CA (1) CA3019676A1 (enExample)
ES (1) ES2909835T3 (enExample)
PL (1) PL3442578T3 (enExample)
PT (1) PT3442578T (enExample)
SI (1) SI3442578T1 (enExample)
WO (1) WO2017181033A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3042583A1 (en) 2016-11-03 2018-05-11 Trillium Therapeutics Inc. Improvements in cd47 blockade therapy by hdac inhibitors
US11802153B2 (en) 2017-10-18 2023-10-31 Forty Seven, Inc. Anti-CD47 agent-based ovarian cancer therapy
EP4129336B1 (en) 2018-02-12 2025-05-07 Forty Seven, LLC Anti-cd47 agent-based treatment of cd20-positive cancer
GB201804860D0 (en) 2018-03-27 2018-05-09 Ultrahuman Two Ltd CD47 Binding agents
CN112601544A (zh) * 2018-07-05 2021-04-02 三钰生物科技股份有限公司 人类抗cd47抗体及其用途
AU2019349651B2 (en) 2018-09-27 2023-12-07 Celgene Corporation SIRP alpha binding proteins and methods of use thereof
US11591390B2 (en) 2018-09-27 2023-02-28 Celgene Corporation SIRP-α binding proteins and methods of use thereof
EP3817773B1 (en) 2018-11-26 2024-07-24 Forty Seven, Inc. Humanized antibodies against c-kit
JP2022510634A (ja) 2018-11-28 2022-01-27 フォーティ セブン， インコーポレイテッド 除去レジメンに抵抗性の遺伝的に改変されたｈｓｐｃ
RS65480B1 (sr) 2019-09-18 2024-05-31 Lamkap Bio Alpha AG Bispecifična antitela protiv ceacam5 i cd3
AU2020410410A1 (en) 2019-12-17 2022-06-09 Pfizer Inc. Antibodies specific for CD47, PD-L1, and uses thereof
CN115361971A (zh) * 2020-04-06 2022-11-18 里兰斯坦福初级大学理事会 抗体制剂
WO2022076928A1 (en) * 2020-10-09 2022-04-14 Sana Biotechnology, Inc. METHODS FOR TRIGGERING SAFETY KILLING MECHANISMS USING A CD47-SIRPα BLOCKADE AGENT
US12071481B2 (en) 2020-12-23 2024-08-27 D-10 Therapeutics, Inc. Anti-CD47 antibodies and uses thereof
WO2022148383A1 (en) * 2021-01-05 2022-07-14 National Institute Of Biological Sciences, Beijing A bispecific antibody targeting gpc3 and cd47
WO2023002415A2 (en) * 2021-07-20 2023-01-26 Magenta Therapeutics, Inc. Methods and compositions for anti-cd117 antibody drug conjugate (adc) treatment
EP4516807A1 (en) 2023-08-28 2025-03-05 Consorcio Centro de Investigación Biomédica en Red Compositions for use in a method of providing improved hematopoietic stem cell engraftment

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2735144T3 (es) 2008-01-15 2019-12-16 Univ Leland Stanford Junior Métodos para manipular fagocitosis mediada por CD47
CN102202643A (zh) * 2008-02-07 2011-09-28 安姆根有限公司 稳定化的蛋白组合物
JP6166177B2 (ja) * 2010-05-14 2017-07-19 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー Ｃｄ４７に対するヒト化及びキメラモノクローナル抗体
SMT202000689T1 (it) 2012-01-17 2021-01-05 Univ Leland Stanford Junior Reagenti per sirp-alfa ad alta affinita'
SG10201700160RA (en) 2012-02-06 2017-03-30 Inhibrx Lp Cd47 antibodies and methods of use thereof
CN105101997B (zh) 2013-02-06 2018-11-09 印希彼有限合伙公司 不减少血小板和不减少血红细胞的cd47抗体及其使用方法
ES2728066T3 (es) * 2013-03-15 2019-10-22 Univ Leland Stanford Junior Métodos para la obtención de dosis terapéuticamente eficaces de agentes anti-CD47
CA2904095A1 (en) 2013-03-27 2014-10-02 Genentech, Inc. Use of biomarkers for assessing treatment of gastrointestinal inflammatory disorders with beta7 integrin antagonists
JP6843611B2 (ja) * 2013-04-29 2021-03-17 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 免疫を強化する抗ｃｄ４７因子の使用
US10172911B2 (en) 2013-10-01 2019-01-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of modulating erythropoiesis with arginine vasopressin receptor 1B molecules
WO2015105995A2 (en) * 2014-01-08 2015-07-16 The Board Of Trustees Of The Leland Stanford Junior University Targeted therapy for small cell lung cancer
WO2015189698A2 (en) * 2014-06-08 2015-12-17 Beijing Cosci-Remd Bio Med Tech Company Ltd Methods for treating type 1 diabetes using glucagon receptor antagonistic antibodies
WO2016028810A1 (en) * 2014-08-18 2016-02-25 Biogen Ma Inc. Anti-cd40 antibodies and uses thereof
US11053314B2 (en) * 2014-10-10 2021-07-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods to eliminate cancer stem cells by targeting CD47
CN115361971A (zh) * 2020-04-06 2022-11-18 里兰斯坦福初级大学理事会 抗体制剂

Also Published As

Publication number Publication date
AU2024203396A1 (en) 2024-06-06
US20190106491A1 (en) 2019-04-11
EP3442578B1 (en) 2022-02-09
ES2909835T3 (es) 2022-05-10
US11718670B2 (en) 2023-08-08
JP2019515899A (ja) 2019-06-13
JP2024059764A (ja) 2024-05-01
KR20240016445A (ko) 2024-02-06
EP4074339A1 (en) 2022-10-19
EP4349412A2 (en) 2024-04-10
CA3019676A1 (en) 2017-10-19
JP7532009B2 (ja) 2024-08-13
PL3442578T3 (pl) 2022-06-20
EP3442578A4 (en) 2019-04-10
CN117695387A (zh) 2024-03-15
WO2017181033A1 (en) 2017-10-19
AU2017250809A1 (en) 2018-10-25
EP4349412A3 (en) 2024-06-12
CN115350276A (zh) 2022-11-18
SI3442578T1 (sl) 2022-05-31
JP2022172278A (ja) 2022-11-15
EP3442578A1 (en) 2019-02-20
AU2017250809B2 (en) 2024-02-29
PT3442578T (pt) 2022-05-19
US20230406923A1 (en) 2023-12-21
KR102505253B1 (ko) 2023-03-02
US11472878B2 (en) 2022-10-18
CN109152837A (zh) 2019-01-04
KR20180134367A (ko) 2018-12-18
US20230068235A1 (en) 2023-03-02
JP7442591B2 (ja) 2024-03-04

Similar Documents

Publication Publication Date Title
KR102505253B1 (ko) 암의 치료에서 항-cd47 제제의 치료적으로 효과적인 용량을 결정하고 달성하는 방법
US20210277115A1 (en) Targeted therapy for small cell lung cancer
US11891450B2 (en) Anti-CD47 agent-based treatment of CD20-positive cancer
AU2014238105B2 (en) Methods for achieving therapeutically effective doses of anti-CD47 agents
HK40107887A (en) Methods for determining and achieving therapeutically effective doses of anti-cd47 agents in treatment of cancer
HK40080891A (en) Methods for determining and achieving therapeutically effective doses of anti-cd47 agents in treatment of cancer
HK40082292A (en) Methods for determining and achieving therapeutically effective doses of anti-cd47 agents in treatment of cancer
EP3668894A1 (en) Treatment of ck8 positive cancers in relation with k-ras gene status
HK40086849A (en) Anti-cd47 agent-based treatment of cd20-positive cancer
WO2023185720A1 (zh) 包含抗ctla4和抗pd1的混合抗体的药物组合物及其治疗用途
HK40029258A (en) Anti-cancer regimen using anti-cd47 and anti-cd20 antibodies

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

PX0601 Decision of rejection after re-examination

St.27 status event code: N-2-6-B10-B17-rex-PX0601

X601 Decision of rejection after re-examination